Zein-Based Nanoparticles Improve the Oral Bioavailability of Resveratrol and Its Anti-inflammatory Effects in a Mouse Model of Endotoxic Shock

Journal of Agricultural and Food Chemistry

Volumn 63, Issue 23, 2015, Pages 5603-5611

  Penalva, Rebeca ^a   Esparza, Irene ^a   Larraneta, Eneko ^a   González Navarro, Carlos J ^a   Gamazo, Carlos ^a   Irache, Juan M ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

anti inflammatory; bioavailability; nanoparticles; resveratrol; zein

Indexed keywords

BIOCHEMISTRY; MAMMALS; RESVERATROL; ZEIN;

ANTI-INFLAMMATORIES; ANTI-INFLAMMATORY EFFECTS; BIOAVAILABILITY; INTRAPERITONEAL ADMINISTRATION; NEGATIVE ZETA POTENTIALS; ORAL BIOAVAILABILITIES; PHARMACOKINETIC STUDIES; TUMOR NECROSIS FACTOR ALPHA;

NANOPARTICLES;

MUS;

ANTIINFLAMMATORY AGENT; DRUG CARRIER; NANOPARTICLE; RESVERATROL; STILBENE DERIVATIVE; TUMOR NECROSIS FACTOR; ZEIN;

ANIMAL; BIOAVAILABILITY; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; FEMALE; HUMAN; IMMUNOLOGY; MALE; MOUSE; ORAL DRUG ADMINISTRATION; RAT; SHOCK, SEPTIC; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AVAILABILITY; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; RATS; RATS, WISTAR; SHOCK, SEPTIC; STILBENES; TUMOR NECROSIS FACTOR-ALPHA; ZEIN;

EID: 84934958401     PISSN: 00218561     EISSN: 15205118     Source Type: Journal    
DOI: 10.1021/jf505694e     Document Type: Article

References (46)

1. Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence Nat. Rev. Drug Discovery 2006, 5, 493-506 10.1038/nrd2060
2. Amri, A.; Chaumeil, J. C.; Sfar, S.; Charrueau, C. Administration of resveratrol: what formulation solutions to bioavailability limitations? J. Controlled Release 2012, 158, 182-193 10.1016/j.jconrel.2011.09.083
3. Kasiotis, K. M.; Pratsinis, H.; Kletsas, D.; Haroutounian, S. A. Resveratrol and related stilbenes: their anti-aging and anti-angiogenic properties Food Chem. Toxicol. 2013, 61, 112-120 10.1016/j.fct.2013.03.038
4. Orallo, F.; Alvarez, E.; Camina, M.; Leiro, J. M.; Gomez, E.; Fernandez, P. The possible implication of trans-Resveratrol in the cardioprotective effects of long-term moderate wine consumption Mol. Pharmacol. 2002, 61, 294-302 10.1124/mol.61.2.294
5. Li, S.; Wang, X.; Kong, L. Design, synthesis and biological evaluation of imine resveratrol derivatives as multi-targeted agents against Alzheimers disease Eur. J. Med. Chem. 2014, 71, 36-45 10.1016/j.ejmech.2013.10.068
6. Singh, G.; Pai, R. S. Recent advances of resveratrol in nanostructured based delivery systems and in the management of HIV/AIDS J. Controlled Release 2014, 194, 178-188 10.1016/j.jconrel.2014.09.002
7. Palsamy, P.; Subramanian, S. Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling Biochim. Biophys. Acta, Mol. Basis Dis. 2011, 1812, 719-731 10.1016/j.bbadis.2011.03.008
8. Timmers, S.; Konings, E.; Bilet, L.; Houtkooper, R. H.; van de Weijer, T.; Goossens, G. H.; Hoeks, J.; van der Krieken, S.; Ryu, D.; Kersten, S. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans Cell Metab. 2011, 14, 612-622 10.1016/j.cmet.2011.10.002
9. Gillum, M. P.; Kotas, M. E.; Erion, D. M.; Kursawe, R.; Chatterjee, P.; Nead, K. T.; Muise, E. S.; Hsiao, J. J.; Frederick, D. W.; Yonemitsu, S.; Banks, A. S.; Qiang, L.; Bhanot, S.; Olefsky, J. M.; Sears, D. D.; Caprio, S.; Shulman, G. I. SirT1 regulates adipose tissue inflammation Diabetes 2011, 60, 3235-3245 10.2337/db11-0616
10. Farghali, H.; Černý, D.; Kameníková, L.; Martínek, J.; Hořínek, A.; Kmoníčková, E.; Zídek, Z. Resveratrol attenuates lipopolysaccharide-induced hepatitis in d -galactosamine sensitized rats: role of nitric oxide synthase 2 and heme oxygenase-1 Nitric Oxide 2009, 21, 216-225 10.1016/j.niox.2009.09.004
11. de la Lastra, C. A.; Villegas, I. Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implications Mol. Nutr. Food Res. 2005, 49, 405-430 10.1002/mnfr.200500022
12. Walle, T. Absorption and metabolism of flavonoids Free Radical Biol. Med. 2004, 36, 829-837 10.1016/j.freeradbiomed.2004.01.002
13. Kuhnle, G.; Spencer, J. P.; Chowrimootoo, G.; Schroeter, H.; Debnam, E. S.; Srai, S. K. S.; Rice-Evans, C.; Hahn, U. Resveratrol is absorbed in the small intestine as resveratrol glucuronide Biochem. Biophys. Res. Commun. 2000, 272, 212-217 10.1006/bbrc.2000.2750
14. Walle, T.; Hsieh, F.; DeLegge, M. H.; Oatis, J. E., Jr.; Walle, U. K. High absorption but very low bioavailability of oral resveratrol in humans Drug Metab. Dispos. 2004, 32, 1377-1382 10.1124/dmd.104.000885
15. Planas, J. M.; Alfaras, I.; Colom, H.; Juan, M. E. The bioavailability and distribution of trans -resveratrol are constrained by ABC transporters Arch. Biochem. Biophys. 2012, 527, 67-73 10.1016/j.abb.2012.06.004
16. Bolko, K.; Zvonar, A.; Gašperlin, M. Mixed lipid phase SMEDDS as an innovative approach to enhance resveratrol solubility Drug Dev. Ind. Pharm. 2013, 40, 102-109 10.3109/03639045.2012.749888
17. Teskač, K.; Kristl, J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol Int. J. Pharm. 2010, 390, 61-69 10.1016/j.ijpharm.2009.10.011
18. Singh, G.; Pai, R. S. Optimized PLGA nanoparticle platform for orally dosed trans-resveratrol with enhanced bioavailability potential Expert Opin. Drug Delivery 2014, 11, 647-659 10.1517/17425247.2014.890588
19. Anderson, T. J.; Lamsal, B. P. Zein extraction from corn, corn products, and coproducts and modifications for various applications: a review Cereal Chem. 2011, 88, 159-173 10.1094/CCHEM-06-10-0091
20. Paliwal, R.; Palakurthi, S. Zein in controlled drug delivery and tissue engineering J. Controlled Release 2014, 189, 108-122 10.1016/j.jconrel.2014.06.036
21. Shi, K.; Kokini, J. L.; Huang, Q. Engineering zein films with controlled surface morphology and hydrophilicity J. Agric. Food Chem. 2009, 57, 2186-2192 10.1021/jf803559v
22. Penalva, R.; Esparza, I.; Agüeros, M.; Gonzalez-Navarro, C. J.; Gonzalez-Ferrero, C.; Irache, J. M. Casein nanoparticles as carriers for the oral delivery of folic acid Food Hydrocolloids 2015, 44, 399-406 10.1016/j.foodhyd.2014.10.004
23. Iacopini, P.; Baldi, M.; Storchi, P.; Sebastiani, L. Catechin, epicatechin, quercetin, rutin and resveratrol in red grape: content, in vitro antioxidant activity and interactions J. Food Compos. Anal. 2008, 21, 589-598 10.1016/j.jfca.2008.03.011
24. Ritger, P. L.; Peppas, N. A. A simple equation for description of solute release I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs J. Controlled Release 1987, 5, 23-36 10.1016/0168-3659(87)90034-4
25. Sujja-areevath, J.; Munday, D. L.; Cox, P. J.; Khan, K. A. Relationship between swelling, erosion and drug release in hydrophillic natural gum mini-matrix formulations Eur. J. Pharm. Sci. 1998, 6, 207-217 10.1016/S0928-0987(97)00072-9
26. Peppas, N. A.; Sahlin, J. J. A simple equation for the description of solute release. III. Coupling of diffusion and relaxation Int. J. Pharm. 1989, 57, 169-172 10.1016/0378-5173(89)90306-2
27. Boocock, D. J.; Patel, K. R.; Faust, G. E. S.; Normolle, D. P.; Marczylo, T. H.; Crowell, J. A.; Brenner, D. E.; Booth, T. D.; Gescher, A.; Steward, W. P. Quantitation of trans -resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2007, 848, 182-187 10.1016/j.jchromb.2006.10.017
28. Kassem, M. A.; ElMeshad, A. N.; Fares, A. R. Enhanced bioavailability of buspirone hydrochloride via cup and core buccal tablets: formulation and in vitro/in vivo evaluation Int. J. Pharm. 2014, 463, 68-80 10.1016/j.ijpharm.2014.01.003
29. Nemzek, J. A.; Hugunin, K. M. S.; Opp, M. R. Modeling sepsis in the laboratory: merging sound science with animal well-being Comp. Med. 2008, 58, 120-128
30. Chen, H.; Zhong, Q. Processes improving the dispersibility of spray-dried zein nanoparticles using sodium caseinate Food Hydrocolloids 2014, 35, 358-366 10.1016/j.foodhyd.2013.06.012
31. Molina, M. I.; Wagner, J. R. The effects of divalent cations in the presence of phosphate, citrate and chloride on the aggregation of soy protein isolate Food Res. Int. 1999, 32, 135-143 10.1016/S0963-9969(99)00086-1
32. Sessa, M.; Balestrieri, M. L.; Ferrari, G.; Servillo, L.; Castaldo, D.; DOnofrio, N.; Donsì, F.; Tsao, R. Bioavailability of encapsulated resveratrol into nanoemulsion-based delivery systems Food Chem. 2014, 147, 42-50 10.1016/j.foodchem.2013.09.088
33. Colom, H.; Alfaras, I.; Maijó, M.; Juan, M. E.; Planas, J. M. Population pharmacokinetic modeling of trans-resveratrol and its glucuronide and sulfate conjugates after oral and intravenous administration in rats Pharm. Res. 2011, 28, 1606-1621 10.1007/s11095-011-0395-8
34. Lin, H. S.; Ho, P. C. Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in Sprague-Dawley rats: the impacts of aqueous solubility, dose escalation, food and repeated dosing on oral bioavailability J. Pharm. Sci. 2011, 100, 4491-4500 10.1002/jps.22588
35. Wenzel, E.; Soldo, T.; Erbersdobler, H.; Somoza, V. Bioactivity and metabolism of trans -resveratrol orally administered to Wistar rats Mol. Nutr. Food Res. 2005, 49, 482-494 10.1002/mnfr.200500003
36. Smoliga, M.; Blanchard, O. Enhancing the delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution? Molecules 2014, 19, 17154-17172 10.3390/molecules191117154
37. Juan, M. E.; Gonzalez-Pons, E.; Planas, J. M. Multidrug resistance proteins restrain the intestinal absorption of trans -resveratrol in rats J. Nutr. 2010, 140, 489-495 10.3945/jn.109.114959
38. Alfaras, I.; Pérez, M.; Juan, M. E.; Merino, G.; Prieto, J. G.; Planas, J. M.; Alvarez, A. I. Involvement of breast cancer resistance protein (BCRP1/ABCG2) in the bioavailability and tissue distribution of trans -resveratrol in knockout mice J. Agric. Food Chem. 2010, 58, 4523-4528 10.1021/jf9042858
39. Kenealey, J. D.; Subramanian, L.; van Ginkel, P. R.; Darjatmoko, S.; Lindstrom, M. J.; Somoza, V.; Ghosh, S. K.; Song, Z.; Hsung, R. P.; Kwon, G. S.; Eliceiri, K. W.; Albert, D. M.; Polans, A. S. Resveratrol metabolites do not elicit early pro-apoptotic mechanisms in neuroblastoma cells J. Agric. Food Chem. 2011, 59, 4979-4986 10.1021/jf104901g
40. Yin, Y.; Yin, S.; Yang, X.; Tang, C.; Wen, S.; Chen, Z.; Xiao, B.; Wu, L. Surface modification of sodium caseinate films by zein coatings Food Hydrocolloids 2014, 36, 1-8 10.1016/j.foodhyd.2013.08.027
41. Wenzel, E.; Somoza, V. Metabolism and bioavailability of trans -resveratrol Mol. Nutr. Food Res. 2005, 49, 472-481 10.1002/mnfr.200500010
42. Kapetanovic, I. M.; Muzzio, M.; Huang, Z.; Thompson, T. N.; McCormick, D. L. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats Cancer Chemother. Pharmacol. 2011, 68, 593-601 10.1007/s00280-010-1525-4
43. Oganesyan, E.; Miroshnichenko, I.; Vikhrieva, N.; Lyashenko, A.; Leshkov, S. Y. Use of nanoparticles to increase the systemic bioavailability of trans-resveratrol Pharm. Chem. J. 2010, 44, 74-76 10.1007/s11094-010-0401-1
44. Pandita, D.; Kumar, S.; Poonia, N.; Lather, V. Solid lipid nanoparticles enhance oral bioavailability of resveratrol, a natural polyphenol Food Res. Int. 2014, 62, 1165-1174 10.1016/j.foodres.2014.05.059
45. Youn, H. S.; Lee, J. Y.; Fitzgerald, K. A.; Young, H. A.; Akira, S.; Hwang, D. H. Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex J. Immunol. 2005, 175, 3339-3346 10.4049/jimmunol.175.5.3339
46. Yang, Y.; Li, S.; Yang, Q.; Shi, Y.; Zheng, M.; Liu, Y.; Chen, F.; Song, G.; Xu, H.; Wan, T.; He, J.; Chen, Z. Resveratrol reduces the proinflammatory effects and lipopolysaccharide-induced expression of HMGB1 and TLR4 in RAW264.7 cells Cell. Physiol. Biochem. 2014, 33, 1283-1292 10.1159/000358696